Pharmaceutical Manufacturing
In 2023, the revenue of the pharmaceutical manufacturing segment by Fosun Pharma amounted to 30,222 million.
To meet the unmet clinical needs, through diversified and multi-level cooperation models such as independent R&D, co-development, license-in and industrial investment, Fosun Pharma continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.
By the end of 2023, the company had more than 70 projects for drugs under development, including innovator drugs, biosimilars. In 2023, the company applied for 206 patents in the pharmaceutical manufacturing segment, including 5 US patents and 11 PCT applications, with 74 patents granted.
-
-
-
Major products of oncology and immunomodulation
Major products of oncology and immunomodulation: Han Qu You (Trastuzumab for Injection), Han Li Kang (Rituximab Injection), Doptelet (Avatrombopag Maleate Tablets), Han Si Zhuang (Serplulimab Injection), Ke Sheng (Xihuang Capsules), Han Da Yuan (Adalimumab Injection), Kai Lai Zhi (Epinastine Hydrochloride Capsules), Zhao Hui Xian (Bicalutamide Tablets), Yi Luo Ze/Tu Mei Si (Pemetrexed Disodium for Injection), Akynzeo (Netupitant and Palonosetron Hydrochloride Capsules), Di Kai Mei (Sorafenib Tosylate Tablets), ondansetron, paclitaxel, and oxaliplatin.
-
-
-
-
Major products of metabolism and digestive System
Major products of metabolism and digestive system: You Li Tong (Febuxostat Tablets), Atomolan (Glutathione Tablets), animal insulin and its preparations, Bei Yi (Potassium Chloride Granules), Ke Yi (New Compound Aloe Capsules), Atomolan (Reduced Glutathione for Injection), Yi Bao (Recombinant Human Erythropoietin for Injection (CHO Cells)), Li Qing (Alfacalcidol Tablets), Wan Su Ping (Glimepiride Tablets), Wan Su Jing (Empagliflozin Tablets), Fan Ke Jia (Lipoic Acid Injection), human insulin and its preparations.
-
-
-
-
Major products of anti-infection
Major products of anti-infection: Comirnaty (mRNA COVID-19 Vaccine), Jie Bei An (Azvudine Tablets), antimalarial series such as artesunate, non-lyophilized rabies vaccine for human use (VERO Cell), Xi Chang/Bi Li Shu (Cefmetazole Sodium for Injection), Sha Duo Li Ka (Potassium Sodium Pehydroandroandrographolide Succinate for Injection), anti-tuberculosis series, Pai Shu Xi Lin (Piperacillin Sodium and Tazobactam Sodium for Injection), Meicelin (Cefminox Sodium for Injection), daptomycin, Qiang Shu Xi Lin/Qin Shu/Er Ye Qin (Piperacillin Sodium and Sulbactam Sodium for Injection), caspofungin, Heptodin (Lamivudine Tablets), Cravit (Levofloxacin Tablets, Levofloxacin Injection), micafungin, vancomycin, Er Ye Bi (Cefizoxime Sodium for Injection), Si Ke Ni (Azithromycin Capsules), Ka Di (Flucloxacillin Sodium for Injection), and Rui Sai Ning (Clindamycin Hydrochloride Capsules).
-
-
-
-
Major products of central nervous system
Major products of central nervous system: Qi Wei (Quetiapine Fumarate Tablets), Qi Cheng (Escitalopram Oxalate Tablets), Chang Tuo Ning (Penehyclidine Hydrochloride Injection), Ao De Jin (Deproteinized Calf Blood Injection), and Lorazepam Tablets.
-
-
-
-
Major products of cardiovascular system
Major products of cardiovascular system: Heparin preparations, Bang Tan (Telmisartan Tablets), Bang Zhi (Pitavastatin Calcium Tablets), Ya Ni An (Amlodipine Besylate Tablets), Ke Yuan (Calcium Dobesilate Capsules), You Di Er (Alprostadil Dried Emulsion for Injection), Xin Xian An (Meglumine Adenosine Cyclophosphate Injection), and Doptelet (Indapamide Tablets).
-
-
-
-
Major products of APIs and intermediates
Major products of APIs and intermediates: Amino acid series, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride.
-